Should You Buy Travere Therapeutics Inc (TVTX) Stock on Monday?

Travere Therapeutics Inc (TVTX) stock is lower by 16.87% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Travere Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TVTX!

See Full TVTX Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With TVTX Stock Today?

Travere Therapeutics Inc (TVTX) stock is trading at $5.52 as of 10:08 AM on Monday, Nov 13, a drop of -$0.06, or -1.08% from the previous closing price of $5.58. The stock has traded between $5.44 and $5.70 so far today. Volume today is less active than usual. So far 102,704 shares have traded compared to average volume of 1,694,244 shares.

More About Travere Therapeutics Inc

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease. Click Here to get the full Stock Report for Travere Therapeutics Inc stock.